Researchers at UC Davis Health reported this week that metformin, a cheap and widely used type 2 diabetes drug, improved mitochondrial function in an animal model of Wilson disease — with the clearest benefit seen in female mice.
The findings appear in a study published in Nature Scientific Reports.
The work matters because Wilson disease is one of the few rare genetic conditions that already has treatments, yet those treatments — copper chelation and dietary restriction — leave a major problem untouched: damage to mitochondria, the structures that power every cell.
Metformin could, in principle, attack both the copper burden and the energy failure. It is also already approved, inexpensive and studied over decades, which shortens the path to human testing compared with a brand-new molecule.
“We’ve been exploring the possibility that we could retask existing drugs to improve mitochondrial function in people with Wilson disease,” said Valentina Medici, first author on the study and professor of gastroenterology and hepatology at UC Davis Health. “There are several drugs that can do this, but metformin is particularly interesting because it’s available on the market and extensively studied.”
The Clinical Takeaway, in Plain English
- Metformin has not been tested against Wilson disease in people. What is new is evidence in mice that it can counteract mitochondrial dysfunction, a damage pattern current drugs do not address.
- Wilson disease is caused by a breakdown in the liver’s ability to shed excess copper, which then accumulates in the liver, brain, eyes and kidneys.
- Women with Wilson disease often have more severe symptoms than men, for reasons that are still unknown — and the new study suggests sex may also shape how patients respond to future therapies.
How Copper Poisons the Cell’s Power Plants
Wilson disease is a rare genetic condition in which the liver loses the ability to excrete copper effectively. Copper then builds up in the body, and the toxic accumulation strikes the liver, brain, eyes and kidneys.
The heaviest collateral damage, according to the UC Davis team, falls on mitochondria. These are the compartments that carry out mitochondrial bioenergetics — the production of enough chemical energy to keep cells running. When mitochondria falter, energy-hungry tissues such as the liver and brain suffer first.

Medici and her co-senior author Cecilia Giulivi, professor of Molecular Biosciences in the UC Davis Weill School of Veterinary Medicine, have focused their research on that energy machinery. The university’s announcement notes the health system is one of 11 Centers of Excellence designated by the Wilson Disease Association, a position the researchers credit for their ability to study the condition in depth.
“We have seen mitochondrial dysfunction in Wilson disease patients and preclinical models,” said Medici. “That inspired us to begin looking for drugs that improve mitochondrial bioenergetics, and metformin seems quite promising.”
Why Existing Chelation Falls Short
Current therapy rests on two pillars: copper chelation — drugs that remove copper from the body — and dietary restrictions that limit copper intake. The UC Davis team’s own assessment, stated in the study coverage, is that chelation has shown only limited efficacy and completely neglects the disease’s mitochondrial impacts.
Metformin offers a second, less obvious mechanism of action — the term for how a drug produces its effects. Best known for lowering blood sugar in type 2 diabetes, it can also bind to metal molecules, including copper. That often-overlooked property is what drew the researchers’ attention: a single approved drug that might both mop up copper and rescue failing mitochondria.
| Approach | What it targets | Status | Key limitation |
|---|---|---|---|
| Copper chelation | Removes excess copper from the body | Established treatment | Limited efficacy; no effect on mitochondrial damage |
| Dietary copper restriction | Reduces new copper intake | Established treatment | Does not clear copper already accumulated |
| Metformin | Mitochondrial dysfunction; binds copper | Investigational — animal model only | Not yet tested in human Wilson disease |
Female Mice Fared Worse — and Responded More
The study’s most striking result is a sex difference. Female mouse models experienced more severe mitochondrial injury than males, yet they also responded more strongly to metformin, with higher levels of the drug measured in their blood. After treatment, their mitochondria became larger, rounder and smoother — structural signs of recovery.
That mirrors a pattern seen in human patients, the researchers note: women with Wilson disease often experience more severe symptoms, for reasons that remain unknown. Ongoing research may provide answers, and any future human use of metformin would have to account for the possibility that men and women respond differently.
From Mouse Model to Medicine Cabinet
A gap separates this finding from a prescription. Metformin is approved for type 2 diabetes; using it for Wilson disease would be off-label until dedicated clinical trials establish that it works in these patients and regulators such as the FDA in the United States or the EMA in Europe review the evidence for that specific use.
Because the drug is already on the market with a decades-long safety record, the repurposing route is faster than developing a new molecule from scratch — but it still requires human trials, which have not yet been announced.
Neither the university’s announcement nor the mirrored coverage carried by Mirage News names the study’s funders; the published paper is the place to check that disclosure. What the reports do establish is the drug’s practical appeal: safe, inexpensive and a mainstay of diabetes care for decades.
Timing also works in the therapy’s favor. Wilson disease symptoms often appear later in childhood, and sometimes in middle age, making the condition particularly amenable to early intervention. A combination of early screening and access to safe, inexpensive therapies could delay or possibly prevent symptoms.
“The ideal situation is to diagnose patients early,” said Medici. “There is some push to add Wilson disease to the list of conditions for newborn screening. We could potentially prevent severe liver disease, acute liver failure and the neuropsychiatric symptoms, which are very difficult to treat in adult patients.”
Wilson Patients Must Not Alter Metformin Alone
Wilson disease patients should not start, stop or alter metformin on their own; any off-label use would be a decision for a hepatologist or genetic specialist, weighed against each patient’s copper levels and liver function.
Metformin itself carries known constraints, long flagged in FDA labeling: it is contraindicated — meaning doctors are advised not to use it — in patients with severe kidney impairment, because reduced clearance of the drug raises the risk of lactic acidosis, a rare but serious buildup of acid in the blood.
People with conditions that deprive tissues of oxygen, or who drink heavily, also face heightened risk and need medical guidance before using the drug.
Anyone with Wilson disease who develops worsening jaundice, abdominal swelling, confusion or new neurological symptoms — tremors, difficulty speaking, mood or personality changes — should seek medical care promptly, since these can signal advancing liver or brain involvement.
What Remains Unanswered
The open questions are the ones the researchers themselves flag. Why women with Wilson disease fare worse than men is unknown. Whether metformin’s mitochondrial benefits in female mice translate to humans has not been tested. And the push to add Wilson disease to newborn screening panels remains just that — a push, not a decision.
The work comes out of UC Davis Health, whose medical center in Sacramento traces its origins to a county hospital established in 1852 and acquired by the University of California in 1973.
Today the 646-bed hospital serves as a referral center for 33 counties and 6 million residents, and it operates the only level I trauma center in inland Northern California — one of fewer than 20 centers in the United States verified for both adults and children. It is the primary teaching hospital of the UC Davis School of Medicine, which opened in 1968.
What is confirmed is narrower but real: in an animal model of the disease, a safe, inexpensive, already-approved drug improved the mitochondrial damage that current treatments ignore. Whether metformin can do the same in people has not yet been shown.
References
- Medici, V., et al. Study on metformin and mitochondrial dysfunction in Wilson disease, Nature Scientific Reports — nature.com/articles/s41598-026-58720-7
- UC Davis Health news release, “Exploring a new treatment for Wilson Disease”
- Mirage News, “Exploring New Treatment For Wilson Disease”